Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

Representative before the EPO

Employment test 11 - 50 employees
Company dna cabinet ores
operating since 1972
1097.21
Headquarter in Paris and 3 offices
active in Legal Services, IP Consulting, and Matchmaking and Trading

Representative before the EPO

Technology company logo thumb
no operation time available
2 offices
Technology Company

We have observed 4 EP applications Elsa Martin-Touaux has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after April 26, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP12305332

A mixture of polar glycolipids for use in the treatment of pain and COPD

IPC classification:
A61K 31/739, A61K 35/74, A61P 11/00, A61P 29/00, C08B 37/00, C12P 19/04, C12R 1/89
Applicant:
Sanofi, S.A.
Agent:
Elsa Martin-Touaux, Sanofi
Status:
APPLICATION WITHDRAWN
EP12305677

CHO expression system

IPC classification:
C12N 15/69, C12N 15/79
Applicant:
Sanofi, S.A.
Agent:
Elsa Martin-Touaux, Sanofi
Status:
APPLICATION WITHDRAWN
EP13843154

MODULATION OF RNA ACTIVITY AND VASCULAR PERMEABILITY

IPC classification:
A61K 31/7088, A61K 48/00, A61P 7/10, A61P 9/00, A61P 35/00, C12N 15/113
Applicant:
University of Sydney
Agent:
Elsa Martin-Touaux, Cabinet Orès
Agent:
Elsa Martin-Touaux, Gevers & Orès
Status:
GRANT OF PATENT INTENDED
EP11802949

ROBO1-FC FUSION PROTEIN FOR USE IN THE TREATMENT OF HEPATOCARCINOMA

IPC classification:
A61K 38/18, C07K 14/475
Applicant:
Sanofi, S.A.
Agent:
Gaëlle Jan, Cabinet Lavoix
Agent:
Elsa Martin-Touaux, Sanofi
Status:
PATENT GRANTED

Please Sign in to use this feature